Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells

Life Sciences

Volumn 90, Issue 19-20, 2012, Pages 770-775

  Zhou, Ning Ning ^a   Tang, Jun ^a   Chen, Wen Dan ^a   Feng, Gong Kan ^a   Xie, Bin Fen ^a   Liu, Zong Chao ^a   Yang, Dajun ^a   Zhu, Xiao Feng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Antitumour activity; Chinese herbal medicine; Her2 neu; Houttuyninum

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOUTTUYNINUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HOUTTUYNIA CORDATA; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HOUTTUYNIA CORDATA; MUS MUSCULUS;

EID: 84860768918     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.03.035     Document Type: Article

References (49)

1. M. Alimandi, L.M. Wang, D. Bottaro, C.C. Lee, A. Kuo, M. Frankel, P. Fedi, C. Tang, M. Lippman, and J.H. Pierce Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors EMBO J 16 18 1997 5608 5617 (Pubitemid 27399853)
2. J. Baselga Treatment of HER2-overexpressing breast cancer Ann Oncol 21 Suppl. 7 2010 vii36 vii40
3. J. Baselga, and S.D. Averbuch ZD1839 ('Iressa') as an anticancer agent Drugs 60 Suppl. 1 2000 33 40 discussion 41-32
4. U. Bohn, J. Aguiar, C. Bilbao, A. Murias, V. Vega, R. Chirino, N. Diaz-Chico, and J.C. Diaz-Chico Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement Int J Cancer 101 6 2002 539 544
5. H.M. Cho, J.D. Rosenblatt, Y.S. Kang, M.L. Iruela-Arispe, S.L. Morrison, M.L. Penichet, Y.G. Kwon, T.W. Kim, K.A. Webster, H. Nechustan, and S.U. Shin Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein Mol Cancer Ther 4 6 2005 956 967 (Pubitemid 40909078)
6. A. Citri, J. Gan, Y. Mosesson, G. Vereb, J. Szollosi, and Y. Yarden Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation EMBO Rep 5 2004 1165 1170 (Pubitemid 40103611)
7. R. Deng, J. Tang, J.G. Ma, S.P. Chen, L.P. Xia, W.J. Zhou, D.D. Li, G.K. Feng, Y.X. Zeng, and X.F. Zhu PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation Oncogene 30 8 2011 944 955
8. P.P. Di Fiore, J.H. Pierce, M.H. Kraus, O. Segatto, C.R. King, and S.A. Aaronson erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells Science 237 4811 1987 178 182 (Pubitemid 17095921)
9. M.P. DiGiovanna, D.F. Stern, S.M. Edgerton, S.G. Whalen, D. Moore II, and A.D. Thor Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients J Clin Oncol 23 6 2005 1152 1160 (Pubitemid 46202271)
10. F.J. Esteva, H. Guo, S. Zhang, C. Santa-Maria, S. Stone, J.S. Lanchbury, A.A. Sahin, G.N. Hortobagyi, and D. Yu PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer Am J Pathol 177 4 2010 1647 1656
11. T. Fehm, W. Jager, S. Kramer, C. Sohn, E. Solomayer, D. Wallwiener, and G. Gebauer Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer Anticancer Res 24 3b 2004 1987 1992 (Pubitemid 38954622)
12. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J.Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R.P. Dong, and J. Baselga Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 12 2003 2237 2246 (Pubitemid 46621858)
13. H. Guan, S.F. Jia, Z. Zhou, J. Stewart, and E.S. Kleinerman Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo Clin Cancer Res 11 5 2005 2008 2017 (Pubitemid 40471867)
14. V. Guarneri, C. Bengala, C. Orlandini, A. Gennari, S. Donati, D. Campani, P. Collecchi, M. Maur, and P.F. Conte HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support Bone Marrow Transplant 34 5 2004 413 417 (Pubitemid 39232370)
15. R.B. Hegeman, G. Liu, G. Wilding, and D.G. McNeel Newer therapies in advanced prostate cancer Clin Prostate Cancer 3 3 2004 150 156 (Pubitemid 40051706)
16. E.S. Henson, X. Hu, and S.B. Gibson Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression Clin Cancer Res 12 3 Pt 1 2006 845 853 (Pubitemid 43259867)
17. M.C. Hung, and Y.K. Lau Basic science of HER-2/neu: a review Semin Oncol 26 4 Suppl. 12 1999 51 59
18. D.P. Korkolis, E. Tsoli, D. Fouskakis, J. Yiotis, G.J. Koullias, D. Giannopoulos, E. Papalambros, N.I. Nikiteas, C.A. Spiliopoulou, E. Patsouris, P. Asimacopoulos, and V.G. Gorgoulis Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients Anticancer Res 24 3b 2004 2061 2068 (Pubitemid 38954634)
19. Li ZB. Research of pharmacological effects of houttuynine analogues. PhD thesis. Southwest University, College of Pharmaceutical Sciences; 2007.
20. S. Li, Q. Yu, and Z. Chu Anti-inflammatory effect of houttuyninum and its mechanism Chin Pharmacol Bull 14 5 1998 442 444 (Pubitemid 28546972)
21. K. Liang, Y. Lu, W. Jin, K.K. Ang, L. Milas, and Z. Fan Sensitization of breast cancer cells to radiation by trastuzumab Mol Cancer Ther 2 11 2003 1113 1120
22. L.D. Locati, G. Rinaldi, P. Bossi, G.P. Dagrada, P. Quattrone, G. Cantu, and L. Licitra Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer Oral Oncol 41 1 2005 97 98 (Pubitemid 39647126)
23. S. Menard, P. Casalini, M. Campiglio, S.M. Pupa, and E. Tagliabue Role of HER2/neu in tumor progression and therapy Cell Mol Life Sci 61 23 2004 2965 2978 (Pubitemid 40104594)
24. R.B. Montgomery, E. Makary, K. Schiffman, V. Goodell, and M.L. Disis Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase Cancer Res 65 2 2005 650 656
25. R. Nahta, and F.J. Esteva Herceptin and early breast cancer: a moment for caution Lancet 366 9498 2005 1673
26. R. Nahta, and F.J. Esteva Herceptin: mechanisms of action and resistance Cancer Lett 232 2 2006 123 138 (Pubitemid 43170962)
27. C.A. Omer, Z. Chen, R.E. Diehl, M.W. Conner, H.Y. Chen, M.E. Trumbauer, S. Gopal-Truter, G. Seeburger, H. Bhimnathwala, M.T. Abrams, J.P. Davide, M.S. Ellis, J.B. Gibbs, I. Greenberg, K.S. Koblan, A.M. Kral, D. Liu, R.B. Lobell, P.J. Miller, S.D. Mosser, T.J. O'Neill, E. Rands, M.D. Schaber, E.T. Senderak, A. Oliff, and N.E. Kohl Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor Cancer Res 60 10 2000 2680 2688 (Pubitemid 30318244)
28. M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S. Ueda, H. Kinoshita, T. Fujii, and M. Kuwano Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol Cancer Ther 3 4 2004 465 472 (Pubitemid 39193724)
29. H. Onuma, B.T. Vander Kooi, J.N. Boustead, J.K. Oeser, and R.M. O'Brien Correlation between FOXO1a (FKHR) and FOXO3a (FKHRL1) binding and the inhibition of basal glucose-6-phosphatase catalytic subunit gene transcription by insulin Mol Endocrinol 20 11 2006 2831 2847 (Pubitemid 44833539)
30. Q.C. Pan, B.F. Xie, and L.J. Xian The pharmacological and immunological study of haxanoyl aldehyde natrium sulfate Acad J Sun Yat-sen Univ Med Sci 8 3 1987 9 14
31. G. Pohl, C.L. Ho, R.J. Kurman, R. Bristow, T.L. Wang, and M. Shih Ie Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations Cancer Res 65 5 2005 1994 2000 (Pubitemid 40478629)
32. J.T. Price, T. Tiganis, A. Agarwal, D. Djakiew, and E.W. Thompson Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism Cancer Res 59 21 1999 5475 5478 (Pubitemid 29526460)
33. G.Z. Rassidakis, M. Feretzaki, C. Atwell, I. Grammatikakis, Q. Lin, R. Lai, F.X. Claret, L.J. Medeiros, and H.M. Amin Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma Blood 105 2 2005 827 829 (Pubitemid 40070771)
34. J.S. Ross, F. Yang, B.V. Kallakury, C.E. Sheehan, R.A. Ambros, and P.J. Muraca HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary Am J Clin Pathol 111 3 1999 311 316 (Pubitemid 29102738)
35. H. Safran, D. Iannitti, R. Ramanathan, J.D. Schwartz, M. Steinhoff, C. Nauman, P. Hesketh, R. Rathore, R. Wolff, U. Tantravahi, T.M. Hughes, C. Maia, T. Pasquariello, L. Goldstein, T. King, J.Y. Tsai, and T. Kennedy Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu Cancer Invest 22 5 2004 706 712 (Pubitemid 40064730)
36. G.K. Scott, C. Marden, F. Xu, L. Kirk, and C.C. Benz Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen Mol Cancer Ther 1 6 2002 385 392
37. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, R.C. Gowan, H. Tecle, S.D. Barrett, A. Bridges, S. Przybranowski, W.R. Leopold, and A.R. Saltiel Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 5 7 1999 810 816 (Pubitemid 29318616)
38. Y. Suarez, L. Gonzalez, A. Cuadrado, M. Berciano, M. Lafarga, and A. Munoz Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells Mol Cancer Ther 2 9 2003 863 872
39. M. Toulany, U. Kasten-Pisula, I. Brammer, S. Wang, J. Chen, K. Dittmann, M. Baumann, E. Dikomey, and H.P. Rodemann Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair Clin Cancer Res 12 13 2006 4119 4126 (Pubitemid 44078101)
40. S. Uddin, A.R. Hussain, K.A. Al-Hussein, P.S. Manogaran, A. Wickrema, M.I. Gutierrez, and K.G. Bhatia Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells Clin Cancer Res 11 8 2005 3102 3108 (Pubitemid 40525217)
41. U. Wilking, E. Karlsson, L. Skoog, T. Hatschek, E. Lidbrink, G. Elmberger, H. Johansson, L. Lindstrom, and J. Bergh HER2 status in a population-derived breast cancer cohort: discordances during tumor progression Breast Cancer Res Treat 125 2 2010 553 561
42. P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K.S. Zanker, L. Kiesel, and B. Brandt HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients Clin Cancer Res 12 6 2006 1715 1720
43. H. Yang, R. Zhao, H.Y. Yang, and M.H. Lee Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity Oncogene 24 11 2005 1924 1935 (Pubitemid 40467584)
44. H. Yang, Y. Zhang, R. Zhao, Y.Y. Wen, K. Fournier, H.B. Wu, H.Y. Yang, J. Diaz, C. Laronga, and M.H. Lee Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt Oncogene 25 33 2006 4585 4594 (Pubitemid 44175117)
45. D.A. Yardley, D. Daniel, M. Stipanov, D.R. Drosick, M. Mainwaring, J. Peyton, M. Shastry, and J.D. Hainsworth A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer Cancer Invest 28 8 2010 865 871
46. H. Yazici, M. Altun, C. Alatli, O. Dogan, and N. Dalay c-erbB-2 gene amplification in nasopharyngeal carcinoma Cancer Invest 18 1 2000 6 10 (Pubitemid 30080778)
47. A. Zaczek, B. Brandt, and K.P. Bielawski The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches Histol Histopathol 20 3 2005 1005 1015 (Pubitemid 40932618)
48. X.F. Zhu, B.F. Xie, J.M. Zhou, G.K. Feng, Z.C. Liu, X.Y. Wei, F.X. Zhang, M.F. Liu, and Y.X. Zeng Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2′,4′-dihydroxy- 6′-methoxy-3′,5′-dimethylchalcone), a component from Chinese herbal medicine Mol Pharmacol 67 5 2005 1444 1450
49. X.F. Zhu, J.S. Wang, L.L. Cai, Y.X. Zeng, and D. Yang SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G phase in breast cancer cells Cancer Sci 97 1 2006 84 89 (Pubitemid 43257032)